Molecular Partners Ag (MOLN) EBT Margin (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly EBT Margin of 97.78% for Q1 2026, up 613.0% year-over-year from 13.71% in Q1 2025, and down 100.07% quarter-over-quarter from 143937.9% in Q4 2025.
Molecular Partners Ag (MOLN) EBT Margin (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported EBT Margin for 7 consecutive years, with 97.78% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 613.0% year-over-year to 97.78%; the TTM figure through Mar 2026 stood at 2203498.66% (up 220350658.0% YoY), while the FY2025 annual figure was 112667814.11%, up 97809218589.0% from the prior year.
- EBT Margin eased to 97.78% in Q1 2026 per MOLN's latest filing, from 143937.9% in the prior quarter.
- Across five years, EBT Margin topped out at 1097586.89% in Q4 2024 and bottomed at 972404.9% in Q2 2024.
- Historically, EBT Margin has averaged 15477.68% across 5 years, with a median of 97.78% in 2026.
- On a YoY basis, EBT Margin climbed as much as 109849606 bps in 2024 and fell as far as 96855261 bps in 2024.
- Molecular Partners Ag's EBT Margin stood at 82.13% in 2022, then sank by 1207 bps to 909.17% in 2023, then soared by 120824 bps to 1097586.89% in 2024, then tumbled by 87 bps to 143937.9% in 2025, then tumbled by 100 bps to 97.78% in 2026.
- Business Quant data shows MOLN's EBT Margin at 97.78% in Q1 2026, 143937.9% in Q4 2025, and 98.26% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.78% |
| Dec 31, 2025 | 143,937.90% |
| Sep 30, 2025 | -98.26% |
| Jun 30, 2025 | -117.79% |
| Mar 31, 2025 | -103.90% |
| Dec 31, 2024 | 1,097,586.89% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | -972,404.90% |
| Mar 31, 2024 | -413.62% |
| Dec 31, 2023 | -909.17% |
| Sep 30, 2023 | -450.18% |
| Jun 30, 2023 | -3,852.29% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 82.13% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | -38.46% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.80% |
| Sep 30, 2021 | -348.40% |
| Jun 30, 2021 | 3.43% |